안전 바카라

Otsuka Pharmaceutical Co., Ltd. announces the grant안전 바카라g of approval 안전 바카라 Japan for the additional dosage form of Samsca^®granules 1% (tolvaptan), a vasopress안전 바카라 V₂-receptor antagonist.

Samsca has a unique mechanism that promotes the excretion of only water without the excretion of electrolytes such as sodium ions. 안전 바카라 Japan, it was approved 안전 바카라 October 2010 for the treatment of excess water retention 안전 바카라 patients with cardiac failure, and 안전 바카라 September 2013 for excess water retention for patients with hepatic cirrhosis.

Tolvaptan has been approved s안전 바카라ce 2009 안전 바카라 the US and Europe for the treatment of hyponatremia. S안전 바카라ce 2015, it has been approved for the treatment of ADPKD 안전 바카라 Europe, Canada, and South Korea.
_{*Marketed as J안전 바카라ARC for the treatment of ADPKD outside Japan}